LeMaitre Vascular (NASDAQ:LMAT) Sees Unusually-High Trading Volume – What’s Next?

LeMaitre Vascular, Inc. (NASDAQ:LMAT) shares saw strong trading volume on Tuesday . 253,150 shares traded hands during mid-day trading, an increase of 99% from the previous session’s volume of 127,513 shares.The stock last traded at $90.91 and had previously closed at $92.10.

Analyst Ratings Changes

Several research analysts recently commented on LMAT shares. JMP Securities increased their price objective on LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a research note on Tuesday, August 20th. Cantor Fitzgerald began coverage on shares of LeMaitre Vascular in a research note on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price target on the stock. StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday. Barrington Research raised their target price on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a research note on Friday, November 1st. Finally, Oppenheimer restated an “outperform” rating and issued a $93.00 price target (up from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $94.57.

LeMaitre Vascular Stock Performance

The stock has a market cap of $2.04 billion, a PE ratio of 49.86, a price-to-earnings-growth ratio of 2.47 and a beta of 0.93. The company’s 50-day moving average price is $97.70 and its 200 day moving average price is $89.71.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The firm had revenue of $54.82 million during the quarter, compared to the consensus estimate of $53.50 million. During the same period last year, the company earned $0.33 EPS. The company’s quarterly revenue was up 15.6% on a year-over-year basis. As a group, equities research analysts predict that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, December 5th. Stockholders of record on Thursday, November 21st were given a dividend of $0.16 per share. The ex-dividend date was Thursday, November 21st. This represents a $0.64 annualized dividend and a dividend yield of 0.70%. LeMaitre Vascular’s dividend payout ratio is currently 34.97%.

Insider Activity

In related news, Director Bridget A. Ross sold 3,750 shares of LeMaitre Vascular stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $101.47, for a total value of $380,512.50. Following the completion of the transaction, the director now owns 2,278 shares in the company, valued at approximately $231,148.66. The trade was a 62.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 10.79% of the company’s stock.

Institutional Investors Weigh In On LeMaitre Vascular

A number of hedge funds have recently added to or reduced their stakes in LMAT. Townsquare Capital LLC increased its position in shares of LeMaitre Vascular by 38.0% during the third quarter. Townsquare Capital LLC now owns 47,953 shares of the medical instruments supplier’s stock worth $4,454,000 after acquiring an additional 13,210 shares during the period. Charles Schwab Investment Management Inc. raised its position in LeMaitre Vascular by 6.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 191,511 shares of the medical instruments supplier’s stock valued at $17,789,000 after purchasing an additional 11,395 shares in the last quarter. Nicholas Investment Partners LP purchased a new position in shares of LeMaitre Vascular in the 2nd quarter valued at about $3,900,000. Creative Planning grew its position in shares of LeMaitre Vascular by 20.7% during the third quarter. Creative Planning now owns 3,594 shares of the medical instruments supplier’s stock worth $334,000 after buying an additional 617 shares in the last quarter. Finally, Copeland Capital Management LLC increased its stake in shares of LeMaitre Vascular by 1.0% during the third quarter. Copeland Capital Management LLC now owns 1,163,392 shares of the medical instruments supplier’s stock worth $108,068,000 after buying an additional 11,318 shares during the period. 84.64% of the stock is currently owned by institutional investors and hedge funds.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.